ABHI 30: NHS Long-Term Plan Promises Diagnosis And Tech Uptake Boost For Industry And Patients

 
• By Ashley Yeo
  
Generate a summary of this article
Listen to this article
Beta

The over-running NHS England Long-Term Plan, to be released in full on Jan. 7, was a central discussion theme at the ABHI’s Market Conference last fall, an occasion that marked 30 years of the association’s support for industry. Early indications about the plan are that digital, early diagnosis, long-term and mental health care are among the key themes and challenges that will be addressed, and supported by the five-year funding boost announced last year. But is the cash settlement enough, and does the plan push the right buttons?

NHS England's new Long-Term Plan, or ten-year plan, will be issued in full later today, half a year late in arriving and having been deferred several times by Brexit, among other things. Drawn up by NHS chief executive Simon Stevens, architect of the NHS Five-Year Forward View in fall 2014, it is the first NHS long-term plan since 2000 – which was billed then as the first big NHS structural change since 1948.

Part-funding of the plan comes via settlement announced in mid-2018, which sees the national provider receive incrementally-rising, real-terms funding...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

SpotifyApple PodcastsWebsite

More from United Kingdom

Global Medtech Guidance Tracker: September 2024

 
• By Vibha Sharma

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 40 documents have been posted on the tracker since its last update.

Biocomposites Fully Acquires SYNICEM And Subiton Lines, Launches NanoBone In UK

 
• By Natasha Barrow

UK-based Biocomposites will begin selling in the UK its next-generation osteoinductive bone graft substitute, NanoBone, which came with its acquisition of Artoss GmbH in June 2023. Meanwhile, the company has purchased remaining shares in the manufacturers of SYNICEM and Subiton antibiotic bone cements and preformed antibiotic-loaded spacers.

Abbott’s Share-Gobbling Aveir DR Leadless Pacing System Introduced To UK

 
• By Natasha Barrow

The firm’s dual-chamber leadless pacemaker system with is expected to be a growth driver for Abbott and already has acquired approximately 30%-40% of market share from Medtronic since its approval by the US FDA in July 2023, according to GlobalData.

Global Medtech Guidance Tracker: August 2024

 
• By Vibha Sharma

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Nearly 80 documents have been posted on the tracker since its last update.

More from Europe

Biocomposites Fully Acquires SYNICEM And Subiton Lines, Launches NanoBone In UK

 
• By Natasha Barrow

UK-based Biocomposites will begin selling in the UK its next-generation osteoinductive bone graft substitute, NanoBone, which came with its acquisition of Artoss GmbH in June 2023. Meanwhile, the company has purchased remaining shares in the manufacturers of SYNICEM and Subiton antibiotic bone cements and preformed antibiotic-loaded spacers.

Abbott’s Share-Gobbling Aveir DR Leadless Pacing System Introduced To UK

 
• By Natasha Barrow

The firm’s dual-chamber leadless pacemaker system with is expected to be a growth driver for Abbott and already has acquired approximately 30%-40% of market share from Medtronic since its approval by the US FDA in July 2023, according to GlobalData.

Amferia Aims To Bring Peptide Hydrogel To Fight Against Antimicrobial Resistance

 
• By Natasha Barrow

Amferia is developing an antimicrobial peptide hydrogel dressing to combat infections in acute wounds in humans and veterinary contexts. Supported by €1.2m of new venture capital financing, the company is planning pivotal clinical studies to support an FDA application later this year and CE mark submission in 2026-2027.